BIO-key International ( (BKYI) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
BIO-key International, Inc. has filed a Form 12b-25, notifying investors of a delay in submitting its Form 10-K (Yearly Report) for the fiscal year ended December 31, 2025. The company’s annual filing will therefore arrive after the normal SEC deadline, drawing attention from shareholders watching its turnaround efforts.
Management cites the time needed to compile, present, and review certain financial information as the key reason for missing the original due date. They state that completing the Form 10-K (Yearly Report) on time would have required unreasonable effort and expense, suggesting internal resource constraints rather than a disclosed accounting or auditor crisis.
BIO-key expects to file the delayed Form 10-K (Yearly Report) as soon as reasonably practicable and, at the latest, within the 15-day extension window allowed under SEC rules. Investors should therefore anticipate the full annual results to be available in mid-April, assuming no further complications emerge.
Preliminary figures point to a weaker top line but a narrower loss year over year. Revenue for 2025 is expected to be about $6.1 million, down from roughly $6.9 million in 2024, while gross profit is projected to fall to about $4.7 million from $5.6 million, reflecting softer sales and margin pressure.
On the cost side, selling, general, and administrative expenses are forecast to decline to around $6.4 million from about $7.1 million, indicating some expense discipline. Basic and diluted loss per share is expected to improve materially to a loss of $0.69, versus a loss of $2.09 in the prior year, though the company still remains unprofitable.
The company cautions that these numbers are preliminary and may change once the reporting process is complete. Investors should treat them as forward-looking and subject to adjustment, as the final audited results could differ from these early estimates.
BIO-key affirms that it has remained current with all other required SEC filings over the past 12 months, signaling an ongoing commitment to regulatory compliance. The Form 12b-25 was signed on March 31, 2026, by Chief Financial Officer Cecilia Welch, underscoring management’s responsibility for the delayed filing and its resolution.
The most recent analyst rating on (BKYI) stock is a Hold with a $0.58 price target. To see the full list of analyst forecasts on BIO-key International stock, see the BKYI Stock Forecast page.
Spark’s Take on BKYI Stock
According to Spark, TipRanks’ AI Analyst, BKYI is a Neutral.
The score is held down primarily by weak financial performance (large ongoing losses and negative cash flow) and bearish technicals (price below key moving averages with negative MACD). The earnings call adds some support via high renewals, defense opportunities, cost control, and improved liquidity, but revenue variability and continued losses keep the overall profile below-average.
To see Spark’s full report on BKYI stock, click here.
More about BIO-key International
Average Trading Volume: 3,332,494
Technical Sentiment Signal: Sell
Current Market Cap: $6.49M
For an in-depth examination of BKYI stock, go to TipRanks’ Overview page.